Literature DB >> 17168701

The pathology induced by highly active antiretroviral therapy against human immunodeficiency virus: an update.

Paul Hofman1, Ann Marie Nelson.   

Abstract

The use of highly active antiretroviral therapy (HAART) has considerably improved the quality of life and has increased the survival of HIV-infected individuals. Although HAART can successfully suppress viral replication in the long term, it is not without significant toxicity, which can seriously compromise treatment effectiveness. Moreover, the rapid rate of virus mutation and subsequent emergence of drug-resistant HIV variants threaten the longer-term efficacy of HIV treatment. The most common adverse effects caused by HAART include a metabolic syndrome with lipodystrophy, hyperlipidemia and insulin resistance, deterioration in the clinical status due to various exaggerated local and systemic inflammatory reactions during the immunerestoration disease, and various hepatic, peripheral and cardiac muscle, kidney, bone, bone marrow, retinal, ear, and skin toxicities. The heterogeneity in the organs affected by the different drugs and the morphological features observed in tissues in HAART-treated patients raise possible explanations including differential distribution or activation of these agents. Antiretroviral drugs from new classes, as well as new drugs from existing classes with favorable resistance and side effect profiles are in various stages of development. However, new tissue disorders will be certainly described in the future in patients treated with these drugs. The different pathophysiology of the main adverse effects and the less common known side effects of antiretroviral therapy against HIV are described here, with special emphasis on the histological features induced by HAART.

Entities:  

Mesh:

Year:  2006        PMID: 17168701     DOI: 10.2174/092986706778742891

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  11 in total

Review 1.  Pathology of infectious diseases: what does the future hold?

Authors:  Paul Hofman; Sebastian Lucas; Grégory Jouvion; Arnault Tauziède-Espariat; Fabrice Chrétien; Gieri Cathomas
Journal:  Virchows Arch       Date:  2017-02-10       Impact factor: 4.064

2.  Ultrasound use to assess Crohn's disease in the UK: a survey of British Society of Gastroenterology Inflammatory Bowel Disease Group members.

Authors:  Shellie Jean Radford; Stuart Taylor; Gordon Moran
Journal:  Frontline Gastroenterol       Date:  2022-01-18

3.  LANA-1, Bcl-2, Mcl-1 and HIF-1alpha protein expression in HIV-associated Kaposi sarcoma.

Authors:  E Long; M Ilie; V Hofman; K Havet; E Selva; C Butori; J P Lacour; A M Nelson; G Cathomas; P Hofman
Journal:  Virchows Arch       Date:  2009-05-30       Impact factor: 4.064

4.  Anti-HIV-1 activity, protease inhibition and safety profile of extracts prepared from Rhus parviflora.

Authors:  Manoj Modi; Boskey Pancholi; Shweta Kulshrestha; Ajay Kumar Rawat; Swadesh Malhotra; Satish Gupta
Journal:  BMC Complement Altern Med       Date:  2013-07-04       Impact factor: 3.659

Review 5.  Clinical use of vaginal or rectally applied microbicides in patients suffering from HIV/AIDS.

Authors:  Satish Kumar Gupta
Journal:  HIV AIDS (Auckl)       Date:  2013-10-22

6.  COHORT PROFILE: The Complications of Long-Term Antiretroviral Therapy study in Uganda (CoLTART), a prospective clinical cohort.

Authors:  Billy Nsubuga Mayanja; Ivan Kasamba; Jonathan Levin; Ivan Namakoola; Patrick Kazooba; Jackson Were; Pontiano Kaleebu; Paula Munderi
Journal:  AIDS Res Ther       Date:  2017-05-04       Impact factor: 2.250

Review 7.  [What place and what future for the pathology of infectious and tropical diseases in France?].

Authors:  Paul Hofman
Journal:  Ann Pathol       Date:  2014-05-20       Impact factor: 0.407

8.  MRN-100, an Iron-based Compound, Possesses Anti-HIV Activity In Vitro.

Authors:  Mamdooh Ghoneum; Magda Shaheen
Journal:  Evid Based Complement Alternat Med       Date:  2008-03-20       Impact factor: 2.629

9.  Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies.

Authors:  Ron Diskin; Florian Klein; Joshua A Horwitz; Ariel Halper-Stromberg; D Noah Sather; Paola M Marcovecchio; Terri Lee; Anthony P West; Han Gao; Michael S Seaman; Leonidas Stamatatos; Michel C Nussenzweig; Pamela J Bjorkman
Journal:  J Exp Med       Date:  2013-05-27       Impact factor: 14.307

10.  Long-term outcomes of oral rehabilitation with dental implants in HIV-positive patients: A retrospective case series.

Authors:  C Gay-Escoda; D Pérez-Álvarez; O Camps-Font; R Figueiredo
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2016-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.